Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328337 | 1.00 | RXRA (0.76) | RXRA | |
| SCHEMBL13328363 | 1.00 | RXRA (0.76) | RXRA | |
| SCHEMBL3295672 | 0.92 | RXRA (0.64) | RXRA | |
| SCHEMBL11957053 | 0.86 | RXRA (1.00) | RXRA | |
| SCHEMBL3290402 | 0.86 | RXRA (1.00) | RXRA | |
| SCHEMBL11957067 | 0.86 | RXRA (1.00) | RXRA | |
| SCHEMBL11957059 | 0.86 | RXRA (1.00) | RXRA | |
| SCHEMBL11957046 | 0.86 | RXRA (1.00) | RXRA | |
| SCHEMBL13328368 | 0.86 | RXRA (0.69) | RXRA | |
| SCHEMBL3292526 | 0.86 | RXRA (0.69) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313923-A1 | METHOD FOR EXTRACTING ALCOHOLS FROM AN INITIAL MIXTURE COMPRISING ALCOHOLS IN AQUEOUS PHASE | IFP Energies nouvelles (FR) | 2024-02-07 | — | — | EP | claimed |
| CN-108636453-B | Nano noble metal catalyst packaged by metal organic framework material and preparation method and application thereof | 浙江工业大学 | 2020-11-13 | — | — | CN | disclosed |
| US-7723371-B2 | Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723326-B2 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090054496-A1 | MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1956909-A1 | MICROBIOCIDES | Syngeta Participations AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007057139-A1 | MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-05-24 | — | — | WO | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-3985754-A | Para-fluorobenzoylpropyl-N-heterocyclic substituted quaternary salts | AMERICAN CYANAMID COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3966748-A | NEUROLEPTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054496-A1 | MICROBIOCIDES | CBR3, CBR1, HDHD5 | RXRA 2747/4885 |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | NR1H2, NR1H3, RXRA | RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.